Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study.

Date publication

août 2024

Journal

Journal of experimental & clinical cancer research : CR

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Pr FALCOZ Pierre-Emmanuel , Dr PENCREACH Erwan

Tous les auteurs :
Petracci E, Pasini L, Urbini M, Felip E, Stella F, Davoli F, Salvi M, Beau-Faller M, Tebaldi M, Azzali I, Canale M, Solli P, Lai G, Amat R, Carbonell C, Falcoz PE, Martinez-Marti A, Pencreach E, Delmonte A, Crinò L, Ulivi P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39169404

Résumé

Factors to accurately stratify patients with early-stage non-small cell lung cancer (NSCLC) in different prognostic groups are still needed. This study aims to investigate 1) the prognostic potential of circulating cell-free (CF) and extracellular vesicles (EVs)-derived microRNA (miRNAs), and 2) their added value with respect to known prognostic factors (PFs).

Mots clés

Humans, Carcinoma, Non-Small-Cell Lung, genetics, Male, Female, Extracellular Vesicles, metabolism, Lung Neoplasms, genetics, Prognosis, Biomarkers, Tumor, Middle Aged, Aged, Prospective Studies, Neoplasm Staging, MicroRNAs, genetics, Circulating MicroRNA, Adult

Référence

J Exp Clin Cancer Res. 2024 08 22;43(1):241